Mrinal Gounder

Phase III Randomized Blinded Trial of Sorafenib vs Placebo in Desmoid Tumor A091105/116279 12/2013

Food and Drug Administration · R01

Contact PI · $874.7K · Sloan-Kettering Inst Can Research

A Study of ERAS-601 in People With Chordoma

Principal investigator · Active not recruiting · Phase 1, Phase 2

Memorial Sloan Kettering Cancer Center

The Severe Von Willebrand Disease (sVWD) Patient Registry

Principal investigator · Recruiting

VWD Connect Foundation

A Study of AL102 in Patients With Progressing Desmoid Tumors

Principal investigator · Active not recruiting · Phase 2, Phase 3

Immunome, Inc.

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Principal investigator · Completed · Phase 3

National Cancer Institute (NCI)